<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00857038</url>
  </required_header>
  <id_info>
    <org_study_id>M07-046</org_study_id>
    <nct_id>NCT00857038</nct_id>
  </id_info>
  <brief_title>Doxycycline and Airway Inflammation in Chronic Obstructive Pulmonary Disease (COPD)</brief_title>
  <official_title>Doxycycline and Airway Inflammation in COPD: A Randomised Placebo Controlled Trial Studying the Effects of Doxycycline on Airway Inflammation in Patients With Moderate and Severe Stable COPD.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical Center Alkmaar</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Leiden University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Amsterdam</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical Center Alkmaar</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      COPD is a progressive pulmonary disease that is characterized by an inflammatory process in
      the airways and the lungs which leads to progressive airway obstruction. The inflammation is
      associated with tissue loss and remodelling. The investigators hypothesized that doxycycline
      reduces neutrophilic airway inflammation in patients with COPD. Therefore the investigators
      will conduct a randomized trial of doxycycline in 30 patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rationale:

      COPD is a disease characterized by chronic inflammation and irreversible airway obstruction.
      Chronic inflammation lead to degradation of extracellular matrix and hereby destruction of
      lung parenchyma. Tetracyclines are known for their anti-inflammatory properties in diseases
      such as rheumatoid arthritis.

      Objective:

      To assess the effect of doxycycline on markers of neutrophilic inflammation and proteolytic
      activity in induced sputum of stable GOLD II and III COPD patients.

      Study population:

      Thirty patients with stable GOLD II COPD.

      Intervention:

      Placebo versus doxycycline in randomised design.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>April 2009</start_date>
  <completion_date type="Anticipated">January 2010</completion_date>
  <primary_completion_date type="Anticipated">August 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>myeloperoxidase in induced sputum</measure>
    <time_frame>3 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>MMP-8, MMP-9, IL-6 levels and differential cell counts in induced sputum.</measure>
    <time_frame>3 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lung function (FEV1)</measure>
    <time_frame>3 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptom scores</measure>
    <time_frame>3 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <condition>Inflammation</condition>
  <condition>Pulmonary Emphysema</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Doxycycline 100mg daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxycycline</intervention_name>
    <description>Doxycycline tablets, 100mg daily</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablets 100mg</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  GOLD II or III COPD (GOLD II: FEV1/FVC &lt; 70%; 50% &lt; FEV1 &lt; 80% predicted, GOLD III:
             FEV1/FVC &lt; 70%; 30% &lt; FEV1 &lt; 50% predicted ).

          -  Stable disease (no exacerbations in the last 3 months).

          -  Age &gt; 40 yrs.

          -  Written informed consent.

        Exclusion Criteria:

          -  Infections and/or use of antibiotics in the last month.

          -  Bacterial colonization of the airways, proven by sputum cultures or broncho-alveolar
             lavage (BAL).

          -  Allergy for tetracyclines or a history of substantial side-effects.

          -  Active respiratory diseases other than COPD (e.g. sarcoidosis, tuberculosis, lung
             cancer, bronchiectasis).

          -  Acute exacerbation of COPD as defined by Anthonisen et al. [10].

          -  Signs and/or symptoms of a current respiratory or non-respiratory infection.

          -  Use of oral or intravenous corticosteroids or other immunosuppressive drugs within the
             last month.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>41 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Wim G Boersma, MD</last_name>
    <phone>0031725482750</phone>
    <email>w.boersma@mca.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Medical Center Alkmaar</name>
      <address>
        <city>Alkmaar</city>
        <state>Noord-Holland</state>
        <zip>1815JD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Wim G Boersma, MD</last_name>
      <phone>0031725482750</phone>
      <email>w.boersma@mca.nl</email>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>March 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 5, 2009</study_first_submitted>
  <study_first_submitted_qc>March 5, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 6, 2009</study_first_posted>
  <last_update_submitted>March 5, 2009</last_update_submitted>
  <last_update_submitted_qc>March 5, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 6, 2009</last_update_posted>
  <responsible_party>
    <name_title>Boersma, MD, PhD</name_title>
    <organization>Medical Center Alkmaar</organization>
  </responsible_party>
  <keyword>COPD</keyword>
  <keyword>Inflammation</keyword>
  <keyword>Neutrophilic</keyword>
  <keyword>Myeloperoxidase</keyword>
  <keyword>Doxycycline</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Emphysema</mesh_term>
    <mesh_term>Pulmonary Emphysema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxycycline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

